• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload.

作者信息

Alavi Samin, Sadeghi Elham, Ashenagar Azin

机构信息

Pediatric Congenital Hematologic Disorders Research Center, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Thalassemia Comprehensive Center, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

出版信息

Blood Res. 2014 Mar;49(1):72-3. doi: 10.5045/br.2014.49.1.72. Epub 2014 Mar 24.

DOI:10.5045/br.2014.49.1.72
PMID:24724073
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3974966/
Abstract
摘要

相似文献

1
Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload.地拉罗司与去铁酮联合口服铁螯合疗法治疗重型β地中海贫血伴持续性铁过载患者的疗效和安全性
Blood Res. 2014 Mar;49(1):72-3. doi: 10.5045/br.2014.49.1.72. Epub 2014 Mar 24.
2
Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study.口服螯合剂地拉罗司与去铁酮联合治疗输血依赖型地中海贫血患儿铁过载的疗效和安全性：一项前瞻性观察研究。
Indian J Pediatr. 2021 Apr;88(4):330-335. doi: 10.1007/s12098-020-03442-5. Epub 2020 Jul 13.
3
Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.不同铁螯合剂对埃及铁过载β地中海贫血患儿的治疗效果。
Infect Disord Drug Targets. 2015;15(2):98-105. doi: 10.2174/1871526515666150724111721.
4
Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia.口服铁螯合剂及其新型组合疗法治疗儿童地中海贫血的疗效和安全性比较
Indian Pediatr. 2016 Mar;53(3):207-10. doi: 10.1007/s13312-016-0821-4.
5
Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.联合口服螯合疗法以最大限度提高输血依赖型重型地中海贫血中铁去除效果的治疗机制 - 一项初步研究。
Expert Rev Hematol. 2019 Apr;12(4):265-272. doi: 10.1080/17474086.2019.1593823. Epub 2019 Mar 28.
6
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.去铁酮与地拉罗司治疗依赖输血的血红蛋白病儿科患者的疗效和安全性评估（DEEP-2）：一项多中心、随机、开放标签、非劣效性3期试验。
Lancet Haematol. 2020 Jun;7(6):e469-e478. doi: 10.1016/S2352-3026(20)30100-9.
7
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.去铁胺、去铁酮和地拉罗司铁螯合疗法治疗非输血依赖型地中海贫血综合征铁过载患者的疗效和安全性。
Drug Des Devel Ther. 2016 Jan 29;10:465-81. doi: 10.2147/DDDT.S79458. eCollection 2016.
8
Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.地拉罗司、去铁酮和去铁胺治疗地中海贫血症患者：通过定量磁共振成像评估心脏铁含量和功能的比较。
Haematologica. 2011 Jan;96(1):41-7. doi: 10.3324/haematol.2009.019042. Epub 2010 Sep 30.
9
Current recommendations for chelation for transfusion-dependent thalassemia.目前对依赖输血的地中海贫血症进行螯合治疗的建议。
Ann N Y Acad Sci. 2016 Mar;1368(1):107-14. doi: 10.1111/nyas.13088.
10
Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior.去铁胺、地拉罗司以及去铁胺与去铁酮联合使用对重型地中海贫血患者肝脏和心脏T2*磁共振成像铁螯合效果的比较
Caspian J Intern Med. 2017 Summer;8(3):159-164. doi: 10.22088/cjim.8.3.159.

引用本文的文献

1
Efficacy of combination chelation with deferasirox and deferiprone in children with beta-thalassemia major: an audit from a unit in the developing world.去铁斯若与去铁酮联合螯合疗法治疗重型β地中海贫血患儿的疗效：来自发展中世界某单位的一项审计
Clin Exp Med. 2025 Aug 22;25(1):299. doi: 10.1007/s10238-025-01687-y.
2
Iron Chelators in Treatment of Iron Overload.铁螯合剂在铁过载治疗中的应用
J Toxicol. 2022 May 5;2022:4911205. doi: 10.1155/2022/4911205. eCollection 2022.
3
Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload.新型联合铁螯合方案用于依赖输血的地中海贫血和严重铁过载患者的安全性和有效性
J Clin Med. 2022 Apr 3;11(7):2010. doi: 10.3390/jcm11072010.
4
Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major.去铁酮与地拉罗司联合铁螯合疗法治疗重度输血依赖型β地中海贫血铁过载患者
Clin Pract. 2017 Jan 12;7(1):912. doi: 10.4081/cp.2017.912. eCollection 2017 Jan 11.

本文引用的文献

1
Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone.重型地中海贫血成年患者的心力衰竭治疗：随机接受去铁胺治疗（加或不加去铁酮）的患者的反应
J Cardiovasc Magn Reson. 2013 May 20;15(1):38. doi: 10.1186/1532-429X-15-38.
2
Recent new drug approvals, part 2: drugs undergoing active clinical studies in children.近期新药获批情况，第二部分：正在儿童中进行积极临床研究的药物。
J Pediatr Pharmacol Ther. 2013 Jan;18(1):14-38. doi: 10.5863/1551-6776-18.1.14.
3
Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.去铁酮（GPO-L-ONE(®)）单药治疗可降低输血依赖型地中海贫血患者的铁过载：来自泰国的多中心前瞻性、单臂、开放标签、剂量递增 III 期儿科研究（GPO-L-ONE；A001）的 1 年结果。
Am J Hematol. 2013 Apr;88(4):251-60. doi: 10.1002/ajh.23386. Epub 2013 Mar 5.
4
Prevalence of iron overload complications among patients with b-thalassemia major treated at Dubai Thalassemia Centre.在迪拜地中海贫血中心接受治疗的重型β地中海贫血患者中铁过载并发症的患病率。
Ann Saudi Med. 2013 Jan-Feb;33(1):18-21. doi: 10.5144/0256-4947.2013.18.
5
Management of transfusional iron overload - differential properties and efficacy of iron chelating agents.输血性铁过载的管理——铁螯合剂的差异特性与疗效
J Blood Med. 2011;2:135-49. doi: 10.2147/JBM.S13065. Epub 2011 Sep 21.
6
Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies.对于一名重型地中海贫血患者，在单药螯合治疗后仍存在严重铁过载的情况下，使用地拉罗司和去铁酮联合进行螯合治疗取得成功。
Br J Haematol. 2011 Sep;154(5):654-6. doi: 10.1111/j.1365-2141.2011.08626.x. Epub 2011 May 25.
7
Combined iron chelation therapy.联合铁螯合疗法。
Ann N Y Acad Sci. 2010 Aug;1202:79-86. doi: 10.1111/j.1749-6632.2010.05591.x.
8
Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.每日交替使用地拉罗司和去铁酮疗法治疗“难以螯合”的重型β地中海贫血患者。
Am J Hematol. 2010 Jun;85(6):460-1. doi: 10.1002/ajh.21711.
9
Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.通过非常强烈的联合螯合作用使全身铁负荷正常化，可逆转重型地中海贫血的心脏和内分泌并发症。
Br J Haematol. 2010 Feb;148(3):466-75. doi: 10.1111/j.1365-2141.2009.07970.x. Epub 2009 Nov 12.
10
T2* magnetic resonance and myocardial iron in thalassemia.地中海贫血中的T2*磁共振成像与心肌铁含量
Ann N Y Acad Sci. 2005;1054:373-8. doi: 10.1196/annals.1345.045.